



## A.forall sharpens its focus

*Retail & Hospital division sold to Abacus Medicine,  
Steen Vangsgaard appointed as CEO of A.forall.*

Anderlecht, 3 september 2025

### A.forall is taking two important steps towards the future.

A.forall has signed a definitive agreement to sell its Retail & Hospital (R&H) business unit — also known as The Pharmacy House — to Abacus Medicine, a pharmaceutical company specializing in parallel import and distribution across Europe. The transaction is expected to close before year-end, subject to customary closing conditions.

At the same time, A.forall announces the appointment of Steen Vangsgaard as its new CEO. He succeeds Filip Van de Vliet, who led the company since 2019 and will transition into the role of Chairman of the Board.

These changes are the result of a deliberate strategic decision: **A.forall is focusing 100% on the development, licensing and commercialization of generic medicines worldwide.**

*“A.forall has made a clear choice and that is to focus fully on generics,” says new CEO Steen Vangsgaard. “Generics are more essential than ever: they **strengthen health systems, reduce costs and improve access**. With this clear focus, we’re aligning all our teams and investments to grow, to reach further, to add value and to make a difference.”*

Over the past years, both the local **Retail & Hospital division** and the global **Generics division** have grown into mature businesses, each with their own rhythm, direction and substantial growth potential. **The divestment of The Pharmacy House to Abacus Medicine allows both organizations to thrive within a sharpened scope.**

The transaction includes all Pharmacy House operations, contracts and teams. The completion is expected before year-end, subject to customary closing conditions.

---

**Filip Van de Vliet**, who served as CEO since 2019, reflects:

*“We’re proud of what we’ve built: two strong businesses, both with a mission to deliver accessible healthcare. Now is the time to give each the focus it deserves. I look forward to continuing to support A.forall as Chairman and to working with Steen to bring the company to the next level.”*

---

**From now on, A.forall is fully dedicated to its generics business.** The company will continue to operate under the A.forall name, with headquarters in Belgium, offices in Ireland and the U.S. and more than 30 value-added products marketed across 60+ countries.

The mission remains unchanged: **#MakingAffordableMedicinesAvailableToAll**.

With a streamlined strategy and a clear direction, A.forall is ready to focus.

Focus to grow. Focus to reach further. Focus to empower.

Focus to make a difference.



**A.forall Group NV**  
Square Marie Curie 50  
1070 Anderlecht - Belgium



Tel.: +32 2 526 64 10  
info@forallpharma.com  
www.aforallpharma.com



VAT/CBE: (BE) 0684.777.042 (RLE Brussels)  
IBAN: BE87 3631 7007 5594 (BIC: BBRUBEBB)



## About A.forall

A.forall is a Belgian group of pharmaceutical companies with headquarters in Anderlecht (Belgium) and additional offices in Ireland and the United States.

At current, A.forall employs over 144 people, and distributes a wide range of pharmaceutical products to pharmacies, wholesalers, hospitals and retirement homes. A.forall is also a global generics player, with 30+ molecules on the European and U.S. market and a fully stocked pipeline of mainly injectable generics and value-added products covering various therapeutic areas. As from now, it will fully focus on its generics business.

For more information, visit: [www.aforallpharma.com](http://www.aforallpharma.com).

## About Filip Van de Vliet

Filip Van de Vliet led A.forall as CEO as from 2019. Under his leadership, the company was restructured and rebranded, and significantly expanded its portfolio and international presence. As Chairman of the Board, he will continue to support A.forall's long-term strategic direction.

## About Steen Vangsgaard

Steen Vangsgaard joined A.forall in November 2024 and brings over 20 years of experience in the generics and specialty pharma industry to the table. Prior to joining A.forall, he held senior regional and global roles at multiple European pharma companies. As CEO, he will lead A.forall's next phase of international growth.

**We're happy to provide additional context or answer any questions you may have.**

**For media inquiries or more information, please contact:**

A.forall Group NV  
Communication Department  
[communications@aforallpharma.com](mailto:communications@aforallpharma.com)  
+32 2 526 64 14



[www.aforallpharma.com](http://www.aforallpharma.com)

### Note to editors:

A.forall, previously known as Alter Pharma or the Alter Pharma Group, is a Belgian group of pharmaceutical companies with headquarters in Anderlecht (Belgium) and offices in Ireland and the United States. Employing in total over 144 employees, the company distributes a wide range of pharmaceutical products to pharmacies, wholesalers, hospitals and retirement homes. At the same time, A.forall is a global player on the generics market, with 30+ molecules on the European and US market and a fully stocked pipeline of niche, complex and added value products.



A.forall Group NV  
Square Marie Curie 50  
1070 Anderlecht - Belgium



Tel.: +32 2 526 64 10  
[info@aforallpharma.com](mailto:info@aforallpharma.com)  
[www.aforallpharma.com](http://www.aforallpharma.com)



VAT/CBE: (BE) 0684.777.042 (RLE Brussels)  
IBAN: BE87 3631 7007 5594 (BIC: BBRUBEBB)